AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20101851 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin alpha exclusively
Number of subjects: 70
Study 20101851 — intervention group
Group type: COMPARATOR
Intervention: Follitropin alpha with 25 IU human chorionic gonadotropin (hCG) daily
Number of subjects: 70
Study 16965680 — intervention group
Group type: EXPERIMENTAL
Intervention: NP (NVB plus DDP)
Number of subjects: 276
Study 16965680 — intervention group
Group type: EXPERIMENTAL
Intervention: TP (TAX plus DDP)
Number of subjects: 276
Study 16965680 — intervention group
Group type: EXPERIMENTAL
Intervention: GP (GEM plus DDP)
Number of subjects: 276
Study 15605667 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 200mg o.d.
Number of subjects: 1124
Study 15605667 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 400mg o.d.
Number of subjects: 1124
Study 15605667 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500mg twice daily
Number of subjects: 1124
Study 15605667 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1124
Study 11689729 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) for 8 weeks, 3 times per week.
Number of subjects: 25
Study 8993241 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high-dose)
Number of subjects: 106
Study 8993241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 8993241 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 106
Study 8993241 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin and Placebo
Number of subjects: 106
Study 8333639 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg IM atropine
Number of subjects: 55
Study 8333639 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 55
Study 3552537 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 49
Study 3552537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 3552537 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 49
Study 31944310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 30
Study 31944310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28869825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus the Memory Support Intervention (CT + Memory Support)
Number of subjects: 48
Study 28869825 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy-as-usual (CT-as-usual)
Number of subjects: 48
Study 27468795 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis + SRP
Number of subjects: 50
Study 27468795 — intervention group
Group type: COMPARATOR
Intervention: Placebo + SRP
Number of subjects: 50
Study 25559332 — intervention group
Group type: EXPERIMENTAL
Intervention: Qur'an recitation
Number of subjects: 60
Study 25559332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 23626461 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg
Number of subjects: 428
Study 23626461 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Number of subjects: 428
Study 23626461 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg plus Metformin
Number of subjects: 428
Study 23626461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study 20655750 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster gait
Number of subjects: 57
Study 20655750 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter steps
Number of subjects: 57
Study 20655750 — intervention group
Group type: EXPERIMENTAL
Intervention: One-standard-deviation decrease in gait speed
Number of subjects: 57
Study 20655750 — intervention group
Group type: EXPERIMENTAL
Intervention: One-standard-deviation decrease in step length
Number of subjects: 57
Study 18266400 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronic acid 5 mg/day
Number of subjects: 138
Study 18266400 — intervention group
Group type: COMPARATOR
Intervention: Risedronic acid 2.5 mg/day
Number of subjects: 138
Study 15932834 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended regimen of norelgestromin/ethinyl E2 transdermal patch (weekly application for 12 consecutive weeks, 1 patch-free week, and 3 more consecutive weekly applications, n = 158)
Number of subjects: 239
Study 15932834 — intervention group
Group type: COMPARATOR
Intervention: Cyclic regimen (4 consecutive cycles of 3 weekly applications and 1 patch-free week, n = 81)
Number of subjects: 239
Study 12792297 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)/NETA (0.025/0.125 mg/day)
Number of subjects: 124
Study 12792297 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 124
Study 11126377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI) therapy
Number of subjects: 0
Study 11126377 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 0
Study 11126377 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI with systemic chemotherapy following hepatic resection
Number of subjects: 0
Study 8971665 — intervention group
Group type: EXPERIMENTAL
Intervention: Needles that remained in place for 10 minutes
Number of subjects: 0
Study 8971665 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxa-only treatment
Number of subjects: 0
Study 8971665 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic acupuncturist (regardless of gender)
Number of subjects: 0
Study 8971665 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic treatment style
Number of subjects: 0
Study 1459154 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg KLH per month for up to 1 year
Number of subjects: 17
Study 1459154 — intervention group
Group type: COMPARATOR
Intervention: No immunostimulator (control group)
Number of subjects: 17
Study 6695853 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (IF RT)
Number of subjects: 68
Study 6695853 — intervention group
Group type: COMPARATOR
Intervention: Involved field radiotherapy (IF RT) plus six cycles of combination chemotherapy (CT)
Number of subjects: 68
Study 6695853 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nodal radiation (TNR)
Number of subjects: 68
Study 6695853 — intervention group
Group type: COMPARATOR
Intervention: Total nodal radiation (TNR) plus CT
Number of subjects: 68
Study 6695853 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 68
Study 31162177 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular vision in glaucoma patients
Number of subjects: 84
Study 31162177 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular vision in glaucoma patients
Number of subjects: 84
Study 31162177 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 84
Study 31162177 — intervention group
Group type: COMPARATOR
Intervention: Young controls
Number of subjects: 84
Study 29550383 — intervention group
Group type: EXPERIMENTAL
Intervention: BP1001 monotherapy (90 mg/m2)
Number of subjects: 39
Study 29550383 — intervention group
Group type: EXPERIMENTAL
Intervention: BP1001 monotherapy
Number of subjects: 39
Study 29550383 — intervention group
Group type: EXPERIMENTAL
Intervention: BP1001 plus low-dose cytarabine
Number of subjects: 39
Study 26836781 — intervention group
Group type: EXPERIMENTAL
Intervention: A+M (amoxicillin and metronidazole)
Number of subjects: 37
Study 26836781 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 37
Study 26836781 — intervention group
Group type: EXPERIMENTAL
Intervention: Az (Azithromycin)
Number of subjects: 37
Study 24625583 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of intramuscular streptomycin
Number of subjects: 151
Study 24625583 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of intramuscular streptomycin
Number of subjects: 151
Study 24625583 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 151
Study 22694808 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal velocity
Number of subjects: 7
Study 22694808 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal velocity
Number of subjects: 7
Study 20214755 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of antiretroviral therapy based on WHO clinical criteria
Number of subjects: 458
Study 20214755 — intervention group
Group type: COMPARATOR
Intervention: WHO clinical stage 3
Number of subjects: 458
Study 20214755 — intervention group
Group type: COMPARATOR
Intervention: WHO clinical stage 4
Number of subjects: 458
Study 17373743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium butyrate coated tablets (1 gram)
Number of subjects: 24
Study 15814544 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205
Study 15814544 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin microemulsion (ME)
Number of subjects: 205
Study 12351331 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (80% of 10RM) for 8 weeks
Number of subjects: 15
Study 12351331 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining after 8 weeks of resistance training
Number of subjects: 15
Study 12351331 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 15
Study 9527962 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 33
Study 9527962 — intervention group
Group type: COMPARATOR
Intervention: Balanced emulsion of long- and medium-chain triglycerides (LCT/MCT)
Number of subjects: 33
Study 8562036 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP1) 1.0 mg/kg
Number of subjects: 41
Study 8562036 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP1) 2.0 mg/kg
Number of subjects: 41
Study 8562036 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP1) 0.5 mg/kg
Number of subjects: 41
Study 8562036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8562036 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP1) (all dosages)
Number of subjects: 41
Study 2653713 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of CTX every 6 hr
Number of subjects: 31
Study 2653713 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of CTX every 8 hr
Number of subjects: 31
Study 2653713 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of CTX every 12 hr
Number of subjects: 31
Study 236806 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 5158
Number of subjects: 10
Study 236806 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 31837393 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-4 fibrosis score (D4FS) derived from gamma-glutamyl transpeptidase (GGT), platelet count, alanine aminotransferase (ALT), and liver stiffness measurement (LSM)
Number of subjects: 77
Study 31837393 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration-controlled transient elastography (VCTE)
Number of subjects: 77
Study 31837393 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 77
Study 31837393 — intervention group
Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 77
Study 31837393 — intervention group
Group type: EXPERIMENTAL
Intervention: AAR
Number of subjects: 77
Study 30222495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding neural mobilization
Number of subjects: 37
Study 30222495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tensioning neural mobilization
Number of subjects: 37
Study 28952214 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH) in obese patients
Number of subjects: 243
Study 28952214 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic hysterectomy (LH) in non-obese patients
Number of subjects: 243
Study 26527776 — intervention group
Group type: COMPARATOR
Intervention: LV5FU2 (bolus/infusional fluorouracil plus leucovorin)
Number of subjects: 2246
Study 26527776 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 (LV5FU2 plus oxaliplatin)
Number of subjects: 2246
Study 26527776 — intervention group
Group type: COMPARATOR
Intervention: LV5FU2
Number of subjects: 2246
Study 26527776 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Number of subjects: 2246
Study 23835291 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of zoledronic acid (ZA) given 1 week before beginning ADT (arm 1)
Number of subjects: 44
Study 23835291 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of zoledronic acid (ZA) given 6 months after beginning ADT (arm 2)
Number of subjects: 44
Study 23835291 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly administration of zoledronic acid (ZA) starting 6 months after beginning ADT for a total of 6 doses (arm 3)
Number of subjects: 44
Study 21812904 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 120
Study 21812904 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 120
Study 21812904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no celecoxib)
Number of subjects: 120
Study 21812904 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg and 400 mg
Number of subjects: 120
Study 20139548 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (0.125% plain bupivacaine)
Number of subjects: 50
Study 20139548 — intervention group
Group type: COMPARATOR
Intervention: Parenteral opioid/sedative (pentazocine/promethazine)
Number of subjects: 50
Study 20139548 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 50
Study 20139548 — intervention group
Group type: COMPARATOR
Intervention: Parenteral opioid/sedative
Number of subjects: 50
Study 16751820 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 minutes continuous brisk walking
Number of subjects: 35
Study 16751820 — intervention group
Group type: EXPERIMENTAL
Intervention: 4x10 minutes brisk walking
Number of subjects: 35
Study 16751820 — intervention group
Group type: COMPARATOR
Intervention: no brisk walking
Number of subjects: 35
Study 15542047 — intervention group
Group type: EXPERIMENTAL
Intervention: Handball group
Number of subjects: 51
Study 15542047 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 12144644 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sodium cromoglycate (SCG) and salbutamol (administered as a nebulized solution)
Number of subjects: 0
Study 12144644 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (administered as a nebulized solution)
Number of subjects: 0
Study 12144644 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) (administered as a nebulized solution)
Number of subjects: 0
Study 9502092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-oral sonography
Number of subjects: 15
Study 7674693 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic approach to cardiac risk stratification including clinical evaluation, functional assessment, and surgical risk assessment.
Number of subjects: 0
Study 2568645 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaclazepam 15 mg per day
Number of subjects: 168
Study 2568645 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 15 mg per day
Number of subjects: 168
Study 192441 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (oral or intravenous)
Number of subjects: 21
Study 192441 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study 31538430 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term exposure to PM10 (exceeding 100 μg/m³)
Number of subjects: 0
Study 31538430 — intervention group
Group type: EXPERIMENTAL
Intervention: Very short-term exposure to PM10 (exceeding 100 μg/m³ for 2 hours)
Number of subjects: 0
Study 31538430 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term exposure to PM2.5 (exceeding 50 μg/m³)
Number of subjects: 0
Study 31538430 — intervention group
Group type: EXPERIMENTAL
Intervention: Very short-term exposure to PM2.5 (exceeding 50 μg/m³ for 2 hours)
Number of subjects: 0
Study 31538430 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term PM10 exposure
Number of subjects: 0
Study 31538430 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term PM2.5 exposure
Number of subjects: 0
Study 28324055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plus GH blockade (pegvisomant)
Number of subjects: 9
Study 28324055 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 9
Study 26482691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutritional guidance with home visits during one year
Number of subjects: 78
Study 26482691 — intervention group
Group type: COMPARATOR
Intervention: Written guide about nutrition in older adults and community‐provided normal care (Control Group)
Number of subjects: 78
Study 23109056 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (GCBT)
Number of subjects: 196
Study 23109056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 196
Study 22110219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactin (PRL)
Number of subjects: 100
Study 22110219 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone (FSH)
Number of subjects: 100
Study 22110219 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone (LH)
Number of subjects: 100
Study 22110219 — intervention group
Group type: EXPERIMENTAL
Intervention: PRL/P+ ratio clustering
Number of subjects: 100
Study 19552866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 19923
Study 19552866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19923
Study 17449505 — intervention group
Group type: EXPERIMENTAL
Intervention: Family based cognitive behaviour counselling programme of four sessions with a trained psychiatric nurse counsellor between three to six months after the suicide.
Number of subjects: 122
Study 17449505 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 122
Study 17449505 — intervention group
Group type: EXPERIMENTAL
Intervention: Family based cognitive behaviour counselling programme
Number of subjects: 122
Study 15333593 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing (21 subjects)
Number of subjects: 40
Study 15333593 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive (COC) (19 subjects)
Number of subjects: 40
Study 11530275 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/day)
Number of subjects: 27
Study 11530275 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (10 mg/day)
Number of subjects: 27
Study 9563738 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (600 mg, four times daily)
Number of subjects: 40
Study 9563738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8169699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin (1 g i.v. every 6 h for four doses)
Number of subjects: 122
Study 8169699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for painful UBCs
Number of subjects: 400
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 400
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial bone substitutes
Number of subjects: 400
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 400
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary stabilization (eg, rodding)
Number of subjects: 400
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment for painless UBCs
Number of subjects: 400
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for high fracture risk in painless UBCs
Number of subjects: 400
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment for fractured, nondisplaced and mildly displaced proximal humerus UBCs
Number of subjects: 400
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment for mildly displaced pathologic humerus shaft fractures
Number of subjects: 400
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment for severely displaced pathologic proximal humerus fractures
Number of subjects: 400
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for severely displaced pathologic proximal humerus fractures
Number of subjects: 400
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for severely displaced humerus shaft fractures
Number of subjects: 400
Study 30925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary stabilization for severely displaced humerus shaft fractures
Number of subjects: 400
Study 31037789 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM intervention
Number of subjects: 100
Study 31037789 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 100
Study 28007766 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead shielding system
Number of subjects: 120
Study 28007766 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation protection drape
Number of subjects: 120
Study 28007766 — intervention group
Group type: COMPARATOR
Intervention: No shielding
Number of subjects: 120
Study 25522743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal group (EA to dorsal segmental acupuncture points BL18‐23 bilaterally)
Number of subjects: 16
Study 25522743 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb group (EA to points in the arms and legs LI10‐LI11, ST36‐Zongping)
Number of subjects: 16
Study 25522743 — intervention group
Group type: COMPARATOR
Intervention: Ear group (EA to ear points in the cavum conchae)
Number of subjects: 16
Study 23674159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 44
Study 23674159 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 44
Study 21864813 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PESs)
Number of subjects: 116
Study 21864813 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 116